TransCode Therapeutics announced initiation of its Phase 1 multicenter, open-label, clinical study of its lead therapeutic candidate, TTX-MC138. Two clinical trial sites have been activated with patient enrollment expected to begin during the current quarter. TransCode may activate a total of up to five clinical trial sites, all of which are expected to be activated this quarter.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAZ:
- TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
- TransCode Therapeutics, Inc. Announces Closing of Public Offering
- Transcode Therapeutics 10M share Spot Secondary priced at 30c
- TransCode Therapeutics, Inc. Announces Pricing of Public Offering
- TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock